Dianthus Therapeutics DNTH Second Development Program — Potential Milestone Payments Due
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept dnth:PotentialMilestonePaymentsDue.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
Upon the achievement, with the first development program with IONTAS, of (i) certain development milestones and (ii) certain commercial milestones, the Company is obligated to make payments to IONTAS of up to £3.1 million (approximately $4.1 million based on the March 31, 2026 exchange rate) and £2.3 million (approximately $3.0 million based on the March 31, 2026 exchange rate), respectively. Upon the achievement, with the second development program with IONTAS, of certain development milestones, the Company is obligated to make payments to IONTAS of up to £2.5 million (approximately $3.3 million based on the March 31, 2026 exchange rate). The Company recorded $0.2 million during each of the three months ended March 31, 2026 and 2025, respectively, for amounts owed under the IONTAS collaborative research license agreement, including milestone payments, within the research and development expenses line item in the unaudited condensed consolidated statements of operations and comprehensive loss.
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's second development program — potential milestone payments due?
- Dianthus Therapeutics (DNTH) reported second development program — potential milestone payments due of $3.3M in Q1 2026.
- How has Dianthus Therapeutics's second development program — potential milestone payments due changed year-over-year?
- Dianthus Therapeutics's second development program — potential milestone payments due increased by 3.1% year-over-year, from $3.2M to $3.3M.
- What does second development program — potential milestone payments due mean?
- This metric represents the total future financial obligations triggered by the achievement of specific clinical, regulatory, or commercial milestones associated with a secondary drug development program. It reflects the contingent liabilities inherent in licensing or collaboration agreements that must be settled as the asset progresses through the development lifecycle. Monitoring these obligations is essential for assessing the capital requirements and cash runway necessary to advance the company's pipeline toward potential commercialization.
Ask your AI about Dianthus Therapeutics's second development program — potential milestone payments due.
Connect your AI assistant and compare it to peers, right in your chat.
